

# SUSPECT ADVERSE REACTION REPORT

## I. REACTION INFORMATION

|  |                              |                  |       |      |         |        |            |                    |            |      |  |
|--|------------------------------|------------------|-------|------|---------|--------|------------|--------------------|------------|------|--|
| 1. PATIENT INITIALS<br>(first, last)<br><b>PRIVACY</b> | 1a. COUNTRY<br><b>PANAMA</b> | 2. DATE OF BIRTH |       |      | 2a. AGE | 3. SEX | 3a. WEIGHT | 4-6 REACTION ONSET |            |      | 8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION<br><br><input type="checkbox"/> PATIENT DIED<br><br><input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION<br><br><input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY<br><br><input type="checkbox"/> LIFE THREATENING |
|  |                              | Day              | Month | Year | Unk     | Female | Unk        | Day                | Month      | Year |  |
|  |                              | <b>PRIVACY</b>   |       |      |         |        |            |                    | <b>Unk</b> |      |  |

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)  
Event Verbatim [LOWER LEVEL TERM] (Related symptoms if any separated by commas)  
can't inject myself because of my disease as it becomes encysted [Injection site cyst]

Case Description: This is a spontaneous report received from a Consumer or other non HCP from medical information team.

A female patient received methotrexate sodium (METOTREXATO).

(Continued on Additional Information Page)

## II. SUSPECT DRUG(S) INFORMATION

|   |  |   |
|---|--|---|
| 14. SUSPECT DRUG(S) (include generic name)<br>#1 ) Metotrexato (METHOTREXATE SODIUM) Solution for injection |  | 20. DID REACTION ABATE AFTER STOPPING DRUG?<br><br><input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NA     |
| 15. DAILY DOSE(S)<br>#1 ) UNK   | 16. ROUTE(S) OF ADMINISTRATION<br>#1 ) Unknown |   |
| 17. INDICATION(S) FOR USE<br>#1 ) Unknown   |  | 21. DID REACTION REAPPEAR AFTER REINTRODUCTION?<br><br><input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NA |
| 18. THERAPY DATES(from/to)<br>#1 ) Unknown  | 19. THERAPY DURATION<br>#1 ) Unknown           |   |

## III. CONCOMITANT DRUG(S) AND HISTORY

|  |  |  |
|--|--|--|
| 22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)   |  |  |
| 23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)<br>From/To Dates      Type of History / Notes      Description<br>Unknown |  |  |

## IV. MANUFACTURER INFORMATION

|  |   |             |
|--|---|-------------|
| 24a. NAME AND ADDRESS OF MANUFACTURER<br>Pfizer S.A.<br>Laura Arce Mora<br>Avenida Escazú, Torre Lexus, piso 7. Escazú<br>San jose, COSTA RICA |   | 26. REMARKS |
|  | 24b. MFR CONTROL NO.<br><b>202500137156</b>   |             |
| 24c. DATE RECEIVED BY MANUFACTURER<br><b>07-JUL-2025</b>   | 24d. REPORT SOURCE<br><input type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE<br><input type="checkbox"/> HEALTH PROFESSIONAL <input checked="" type="checkbox"/> OTHER: Spontaneous |             |
| DATE OF THIS REPORT<br><b>10-JUL-2025</b>  | 25a. REPORT TYPE<br><input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:  |             |

25b. NAME AND ADDRESS OF REPORTER  
NAME AND ADDRESS WITHHELD.

---

**ADDITIONAL INFORMATION****7+13. DESCRIBE REACTION(S) continued**

The patient's relevant medical history and concomitant medications were not reported.

The following information was reported: INJECTION SITE CYST (non-serious), outcome "unknown", described as "can't inject myself because of my disease as it becomes encysted". The action taken for methotrexate sodium was unknown.

Additional Information: The patient reported: "I want to get methotrexate 2.5 mg orally, as I can't inject myself because of my disease as it becomes encysted. Where can I get oral medication?"